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Autoantibodies to the smaller isoform of glutamate decarboxylase (GAD) can be
found in patients with type 1 diabetes and a number of neurological disorders,
including stiff-person syndrome, cerebellar ataxia and limbic encephalitis. The detection
of disease-specific autoantibody epitopes led to the hypothesis that distinct GAD
autoantibodies may elicit specific neurological phenotypes. We explored the in
vitro/in vivo effects of well-characterized monoclonal GAD antibodies. We found
that GAD autoantibodies present in patients with stiff person syndrome (n = 7)
and cerebellar ataxia (n = 15) recognized an epitope distinct from that recognized
by GAD autoantibodies present in patients with type 1 diabetes mellitus (n = 10)
or limbic encephalitis (n = 4). We demonstrated that the administration of a
monoclonal GAD antibody representing this epitope specificity; (1) disrupted in
vitro the association of GAD with γ-Aminobutyric acid containing synaptic vesicles;
(2) depressed the inhibitory synaptic transmission in cerebellar slices with a gradual
time course and a lasting suppressive effect; (3) significantly decreased conditioned
eyelid responses evoked in mice, with no modification of learning curves in the
classical eyeblink-conditioning task; (4) markedly impaired the facilitatory effect exerted
by the premotor cortex over the motor cortex in a paired-pulse stimulation paradigm;
and (5) induced decreased exploratory behavior and impaired locomotor function
in rats. These findings support the specific targeting of GAD by its autoantibodies
in the pathogenesis of stiff-person syndrome and cerebellar ataxia. Therapies of
these disorders based on selective removal of such GAD antibodies could be
envisioned.
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Introduction
Conversion of glutamate to GABA is catalyzed by two isoforms
of glutamate decarboxylase (GAD): GAD67 and GAD65.
Autoantibodies to the smaller isoform (GAD65Ab) can be found
in patients with type 1 diabetes, and a number of neurological
disorders, including stiff-person syndrome (SPS), cerebellar
ataxia (Björk et al., 1994; Honnorat et al., 2001; Rakocevic et al.,
2006), and limbic encephalitis (Matà et al., 2010) while GAD67 is
rarely autoantigenic.
The hypothesis that GAD65Ab specifically target and impair
GAD65 function in neurological diseases is supported by
passive transfer experiments of GAD65Ab. In vivo injections
of rat or mouse brain with monoclonal GAD65Ab or purified
immunoglobulin obtained from GAD65Ab-positive sera of
SPS patients induced increased excitability of the spinal cord
(Manto et al., 2011), increase of neuronal synaptic function
(Vega-Flores et al., 2014), stiffness-like motor deficits (Hansen
et al., 2013), behavioral changes including anxiety (Geis et al.,
2011), and changes in cognitive functions (Hampe et al.,
2013).
In our previous studies we established that monoclonal
GAD65Ab with different epitope specificities induced distinct
neurological changes when injected in vivo. This strongly
supports our hypothesis that distinct neurological symptoms
in GAD65Ab-associated neurological diseases and the apparent
lack of such symptoms in patients with type 1 diabetes are
caused by disease-specific GAD65Ab (Manto et al., 2007, 2011;
Hampe et al., 2013; Vega-Flores et al., 2014). However, it
remained crucial to establish GAD65 as the pathogenic target of
GAD65Ab.
We performed novel studies towards the pathogenic
mechanisms involved, demonstrating that patients with SPS and
cerebellar ataxia develop GAD65Ab recognizing disease-specific
epitopes, and inhibiting the enzyme activity of GAD65. We
analyzed the effect of GAD65-specific monoclonal antibodies
on the co-localization of GAD65 with GABAergic synaptic
vesicles and cerebellar GABAergic inhibition in rats as well
as in wild-type (WT) and GAD65-knockout (KO) mice.
Subsequently we relayed our findings to the interpretation of
in vivo studies of the effects of GAD65-specific monoclonal
antibodies on (a) learning and memory acquisition in mice
(classical eyeblink conditioning); (b) corticomotor responses in
rats; and (c) anxiety-related behavior in rats.
Materials and Methods
Patients
Sera of patients diagnosed with cerebellar ataxia (n = 15), SPS
(n = 7), and limbic encephalitis (n = 4) were included in this
study. Ten patients diagnosed with type 1 diabetes without
neurological symptoms were included as controls. Clinical
parameters including age, gender, neurological diagnosis, and
presence of other autoimmune diseases are summarized in
Table 1 along with GAD65Ab results, including titer and
epitope specificities. Written consent was obtained from all
patients. This study was approved by the institutional review
board of the University Claude Bernard Lyon 1 and Hospices
Civils de Lyon.
Monoclonal Antibodies Used in this Study
Human monoclonal antibodies b96.11 and b78 and mouse
monoclonal antibody N-GAD65mAb specific to GAD65 were
described before (Hampe et al., 2001; Manto et al., 2011).
The antibodies were isolated by Protein G Sepharose from
supernatants of the respective B cell lines or hybridoma and
the protein concentration was adjusted to 1 mg/ml. Notably,
only b78 inhibits the enzyme activity of GAD65 (Raju et al.,
2005). Human monoclonal antibody HAA1 (ATCC Manassas
VA, USA, ATCC number: HB-8534) is directed against Blood
group A antigen and served as a control.
GAD65Ab Radioligand Binding Assay and
Epitope Mapping
GAD65Ab titers were determined by radioligand binding
assay (RBA; Grubin et al., 1994; Bingley et al., 2003). The
intra-assay coefficient of variation (CV) was 7.6%. In the
International Combined Autoantibody Workshop, our assay
showed 70% sensitivity and 98% specificity. The World Health
Organization (WHO) standard (Mire-Sluis et al., 2000) was
included as a standard to express immunoglobulin binding
levels as a relative Unit (U/ml). The range of the standard
curve was 30–1,000 U/ml. Samples that exceeded the upper
end of the standard curve were titrated to half-maximal
binding. Epitope mapping of GAD65Ab was performed on
samples at half-maximal binding as previously described
(Hampe et al., 2007). The cutoff for specific competition was
determined as ≤15% as previously described (Hampe et al.,
2007).
Immunoisolation of GABAergic Synaptic Vesicles
Synaptic vesicles were prepared fromwhole rat brain as described
by (Huttner et al. (1983). Briefly, synaptosomes were prepared by
homogenizing fresh or frozen rat brain followed by a series of
differential and sucrose-gradient centrifugation steps. Fractions
containing the synaptic vesicle markers synaptophysin were
pooled. Monoclonal antibody N-GAD65mAb crosslinked to
Protein A Sepharose (PAS) was used to enrich for GABAergic
vesicles. N-GAD65mAb-PAS was incubated with the pooled
fractions for 2 h at 4◦C while rotating. Bound immune
complexes were washed extensively and analyzed for the
presence of synaptophysin by Western blot utilizing a polyclonal
anti-Synaptophysin rabbit antibody (Thermo Fisher Scientific,
Rockford, IL, USA).
Un-coupling of GAD65 from GABAergic Vesicles
To test whether b78 and/or b96.11 interfered with the association
of GAD65 with GABAergic vesicles, we incubated the synaptic
vesicle preparation with either monoclonal antibody (7 µg) for
1 h on ice. Human monoclonal antibody HAA1 was used as a
negative control. After the initial incubation GABAergic vesicles
were isolated as described above and the immunoprecipitated
proteins were analyzed for the presence of synaptophysin.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 2 March 2015 | Volume 9 | Article 78
Manto et al. Pathogenic mechanisms affected by GAD65Ab
TABLE 1 | Characteristics of patients included in the study.
CA LE SPS Type 1 diabetes
Other Autoimmune diseases Type 1 diabetes,
Hashimoto
Hashimoto, Stiff
Leg Syndrome
Type 1 diabetes none
N 15 4 7 10
Age 60 (32–82) 44 (24–60) 45 (29–89) 12 (7–15)
Gender 11 F/4 M 4 F 7 F 4 F/6 M
GAD65Ab titer (U/ml) 6.0 × 105
(3.9 × 104–8.9 × 106)
6.2 × 105
(7.6× 104–1.5× 106)
1.1 × 106
(2.5× 105–4.6× 106)
348 (341–1136)
GAD65 binding in the presence of rFab b78 (%) 81 (67–100 88 (79–94) 77 (66–81) 97 (87–99)
GAD65 binding in the presence of rFab b96.11 (%) 73 (44–94) 69 (58–99) 75 (55–78) 64 (42–85)
Values are reported as median with range.
Patch-clamp Recordings of Cerebellar
GABAergic Transmission
Experiments were performed on thin cerebellar slices from
Sprague-Dawley rats (ages: 12–15 days, both sexes) as described
previously (Saitow et al., 2005), in C57BL/6 WT mice and
GAD65-KO mice back-crossed onto C57BL/6 (Yanagawa
et al., 1999; Yamamoto et al., 2004) (ages: 14–18 days).
Parasagittal slices of the brain (250 µm thickness) were
superfused with artificial cerebrospinal fluid (ACSF) in 6-cyano-
7-nitroquinoxaline-2, 3-dione (CNQX) (10 µM) (Tocris
Cookson Bristol, UK) to eliminate glutamatergic excitatory
synaptic responses.
Whole-cell voltage-clamp recordings held at −50 mV from
Purkinje cells (PCs) were performed as previously described
(Saitow et al., 2005). Individual slices were transferred to a
recording chamber attached on the stage of a microscope
(BX61WI, Olympus, Japan) and continuously perfused with
oxygenated ACSF at a flow rate of 1.3–1.5 ml/min at 25–27◦C.
Monoclonal antibodies (diluted to 10 µg/ml in ACSF) were
applied by perfusion for 10 min. For recording GABAergic
miniature inhibitory postsynaptic currents, the cells were voltage
clamped at −20 mV in order to increase electromotive force for
GABAergic currents. Responder cells were defined as showing
Ab-induced inhibition 3 min after the bath application, which
lasted for more than 20min and an inhibition rate >20% (percent
changes in the IPSC before and after was below 80%). All
animal experiments were approved by the Ethics Review Board
of Nippon Medical School.
Eyeblink Conditioning
Experiments were carried out on 3 months old, male C57BL/6
mice (University of Seville Animal House, Seville, Spain).
All of the experiments were carried out in accordance to
European Union (2003/65/CE) and Spanish (BOE 252/34367-
91,2005) guidelines for the use of laboratoryanimals in chronic
experiments and were approved by the Ethical Committee of the
Pablo de Olavide University.
Surgical Preparation for Classical Eyeblink
Conditioning
Anesthetized mice were implanted with two EMG recording
electrodes in the left orbicularis oculi muscle and a pair of
recording electrodes aimed to the ipsilateral supraorbital nerve.
Electrodes were made of Teflon-insulated, annealed stainless
steel wire (50 µm in diameter, A–M Systems, Carlsborg, WA,
USA). An electrode was fixed to the cranial bone as ground.
Electrodes were connected to a 6-pin socket (RS-Amidata,
Madrid, Spain), which was fixed with dental cement to the
cranial bone. Animals were also implanted with a C315GS-
4 stainless steel cannula (Plastic One, Reanoke, VA) on the
ipsilateral interpositus nucleus (1.2 mm lateral and 6.36 mm
posterior to bregma and 3 mm from brain surface, i.e., 0.25 mm
above the infusion target (Paxinos and Franklin, 2001) for b78
administration. After surgery, animals were kept in independent
cages, with free access to food and water, and allowed proper
recovery (1 week) before the beginning of the experiment.
Classical Conditioning Procedures of Eyelid
Responses
Classical conditioning of eyelid responses were performed as
previously described (Guerra-Narbona et al., 2013), using 10
animals per group and trace and delay conditioning paradigms.
Briefly, a short (for trace) or long (for delay) tone was used as
conditioning stimulus (CS), whilst an electrical shock applied
to the supraorbital nerve (presented 250 ms from CS start) was
used as unconditioned stimulus (US). Conditioned responses
were determined from the EMG activity evoked in the orbicularis
oculi muscle during the CS-US interval. The rectified area of
EMG activity during the same interval was used to determine
eyelid performance during conditioned eyeblinks (Domínguez-
del-Toro et al., 2004; López-Ramos et al., 2010). A total of one
habituation, five conditioning, and one extinction sessions (120
trials each) were presented to each animal in seven successive
days. Only the first fifty trials of each session were analyzed
(Gruart et al., 2006; López-Ramos et al., 2010). Prior (30 min)
to each conditioning and extinction session, b78 (1.5 µg) or
saline (1.5 µl) was administered through an injection cannula.
The injection cannula was 250 µm longer than the implanted
cannula, which was used as a guide. Location of the implanted
cannula was verified as described previously (Gruart et al., 2012).
Distribution of infused GAD65Ab in the deep cerebellar nuclei
was confirmed by immunohistochemistry on cerebellar slices.
Data Collection and Analysis of Eyelid Responses
Data were recorded and analyzed as described previously
(Guerra-Narbona et al., 2013). Criteria for conditioned responses
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were as before (Domínguez-del-Toro et al., 2004; López-Ramos
et al., 2010; Guerra-Narbona et al., 2013). EMG and 1-V
rectangular pulses corresponding to CS and US presentations
were stored digitally on a computer through an analog/digital
converter (CED 1401 Plus, Cambridge, England). Collected
EMG data were quantified through a purpose-designed Excel
worksheet, as the percentage of conditioned responses per
session—i.e., the proportion of paired CS-US stimulations within
a session of 50 presentations that generated an EMG activity
satisfying the above-mentioned criteria (Domínguez-del-Toro
et al., 2004; López-Ramos et al., 2010). In addition data were
analyzed off-line for quantification of rectified EMG area
(µV× s) with the Spike 2 (CED) program.
Modulation of Corticomotor Excitability
Experiments were approved by the Animal Care Committee of
ULB. Rats were bred in the local animal care facility and received
water and food ad libitum.
Infusion of Ab
Adult anesthetized Wistar rats (weight: 206–420 gr, 25 males, 22
females) were implanted with guides (CMA12, CMA, Sweden)
in the left cerebellar interpositus nucleus (coordinates related to
bregma: −11.6, L: +2.3, V: −4.6 (Paxinos and Watson, 2007).
A needle (Hamilton point style 4, Hamilton) was inserted in
the guide. The extremity of the needle was located 0.2 mm
below the extremity of the guide. Monoclonal antibodies or
controls (total volume: 5 µl of 1 mg/ml) were infused using
a micropump (CMA100, CMA, Sweden) at a flow rate of
1 µL/min. Animals were infused with Ringer solution (n = 9)
(Group 1), b96.11 (n = 10) (Group 2), or b78 (n = 7) (Group 3).
A fourth group of four rats was infused with b78 in the
fastigial nucleus (coordinates related to bregma: −11.8, L: +0.5,
V: −5.4), to assess the effect of the zone injected in the
cerebellum.
To exclude local bleeding following the experimental
procedures, we monitored the local blood flow at the beginning
and end of the experiments using laser flowmetry (Oxylab,
Oxford Optronix). A laser flow probe was inserted near the
tip of the guide to monitor the blood flow locally in the
brain (microvascular perfusion). This technique allows the
early detection of bleeding (immediate drop in blood flow)
and was validated in 12 rats. Blood flow rates (expressed in
arbitrary units BPU (blood per units) allowing evaluation of
relative changes in perfusion; see Tonnesen et al., 2005) at
the beginning and end of each experiment were determined.
Rats with impaired blood flow were excluded from the
analysis.
Analysis of Corticomotor Excitability
Muscle recordings were performed as previously described with
minor modifications (Hosoido et al., 2009). For forelimbs and
hindlimbs, we analyzed the corticomotor responses evoked in
interosseus muscles on the left side following stimulation of
the right motor cortex (Oulad Ben Taib et al., 2005). We used
subcutaneous electrodes (Technomed 017K025) implanted in
interosseus muscles. The impedance was kept below 5 K.
In previous studies, we determined the ‘‘hot spot’’ of the
gastrocnemius muscle (Oulad Ben Taib et al., 2005). This
allowed us to identify the precise location corresponding to the
largest motor evoked potential (MEP; confirmed by epidural
stimulation with tungsten microelectrodes TM33A05, World
Precision Instruments, UK), which was found to be located
between 2–4 mm laterally, and between 1 mm anterior and 2 mm
posterior (coordinates related to bregma). A similarmethodology
for mapping of MEPs (identification of the hot spot for each
muscle) was applied here. The duration of stimuli was 1 ms
(square waves; NeuroMax 4, Xltek, Canada). Recruitment curves
(detection of motor threshold MT defined as the lowest intensity
eliciting at least five out of 10 evoked responses with an amplitude
>20µV, followed by increases of the intensity of stimulation with
steps of 0.1 mA until a plateau) of corticomotor responses were
analyzed to confirm the classical sigmoid course using a sigmoid
fitting with three parameters: y = a/(1+ exp(−(x− x0)/b))
(Oulad Ben Taib et al., 2005). Subsequently, motor cortex was
stimulated at an intensity of 130% of MT to assess corticomotor
potentials. Peak-to-peak amplitudes in motor responses of the
left interosseus muscles were studied for groups of 10 successive
corticomotor responses (Filter settings were 30 Hz–1.5 kHz;
NeuroMax 4, Xltek, Canada).
Paired-Pulse Corticomotor Responses
At a short latency between a peripheral nerve stimulus and
a second stimulus (called test stimulus) applied contralaterally
on motor cortex, the corticomotor response is increased due
to facilitation (pairing effect) (Oulad Ben Taib et al., 2005;
Oulad Ben Taib and Manto, 2008). To evaluate these paired-
pulse corticomotor responses, test stimuli on right motor cortex
(NeuroMax 4, Xltek, Canada) were preceded by a first inter-
stimulus interval (ISIs) of 4 ms and in contralateral sciatic nerve
(for hindlimbs) at an ISI of 6 ms (Oulad Ben Taib and Manto,
2008). For forelimbs, we used ISIs of 10 and 14 ms in three rats to
confirm our observations and to exclude a contribution of a pure
spinal facilitation.
Trains of High-Frequency Stimulation (HFS) Over rFr2
Trains of stimulation were applied in right prefrontal region rFr2
as described previously (Oulad Ben Taib and Manto, 2008) with
minor modifications. Trains of HFS consisted in 25 successive
rectangular pulses, with a pulse duration of 500 µs and an intra-
train interval between two successive pulses of 1 ms (1000 Hz).
Trains were repeated every 50 ms for a period of 14 min. We
studied here the effects of premotor HFS on the paired-pulse
corticomotor responses.
Corticomotor responses were analyzed at baseline (a) without
(unpaired motor responses UMR); and (b) with a preceding
stimulus (paired-pulse motor responses CMR). Following
infusion in cerebellar nuclei, corticomotor responses were re-
assessed between 30 and 45 min after infusion without and with
preceding stimulus (to evaluate the infusion effect). Trains of
HFS were applied subsequently and the corticomotor responses
were re-assessed immediately (at a timing of ∼65–80 min
after infusion) after, both without and with a pairing stimulus
immediately after (HFS effect) (Manto et al., 2011).
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Behavioral Data
We assessed the effects of intra-nuclear administration of
GAD65Ab bilaterally upon the exploration behavior (open field)
and upon locomotor activity (beam test). Rats were assessed 6 h
after the administration of GAD65Ab, using two digital cameras
(Canon ZR40). Displacement times and number of squares
crossed were obtained by extracting manually the position of
rats from digitally reconstructed images using the APAS system
(Ariel Dynamics, USA). The images were filtered using a Sobel
filter providing contrasted pictures by emphasizing edges and
transitions. The spatial accuracy was 1.5 mm. The sampling
rate was 60 Hz. The reproducibility of the method has been
assessed with 2 independent observers (beam test: Pearson
product moment correlation = 0.958; open field: Pearson product
moment correlation = 0.974). For the open field test (square open
field of 68 × 68 × 29 cm; divided in 25 identical squares), rats
were placed at the center of the open field at the beginning of
the procedure. They were first left undisturbed for 40 min before
testing. The number of squares crossed over a period of 3 min
was counted. Animals in groups of five rats were infused with
b78 (Group 1), b96.11 (Group 2), Ringer solution (Group 3), or
no injection (sham procedure: anesthesia with chloral hydrate,
surgical opening of the skin immediately followed by suture)
(Group 4). Five trials were performed for each rat. The arena
was cleaned carefully between each measurement. For the beam
test, rats had to traverse an elevated horizontal beam of 80 cm.
We counted the displacement time from a starting box to a goal
box. During a short training period (10 trials), the animal was
repeatedly placed on the beam in the starting box to move to the
goal box without interruption.
Histological Verification
At the end of the experiments, brains were extracted from the
skull to exclude a traumatic lesion (Manto et al., 2011). We
assessed brain sections similar to a method previously published
(Bert et al., 2004). Only data with correct location of the guide
(the extremity of the guide located in the target region) were
analyzed.
Statistical Analysis
Differences in GAD65Ab titer and epitope specificities were
determined using Kruskal-Wallis test. The extent of the
inhibitory effect of each antibody in the cerebellar slide studies
were compared using the Tukey-Kramer multiple comparison
test. Cumulative curves were compared using the Kolmogorov-
Smirnov (K-S) test. Regarding the modulation of the excitability
of corticomotor responses in rats, for both forelimbs and
hindlimbs, we applied an analysis of variance to compare the
amplitudes of MEPs in the groups 1–3 at baseline before paired
stimulation (in order to exclude differences between the three
groups at the beginning of the experiments). For MEPs in both
forelimbs and hindlimbs, we assessed the effects of the paired-
pulse procedure (ratios CMR/UMR = ratios paired corticomotor
responses/unpaired corticomotor responses) in the three groups
and in the three states (basal state, post-injection and post-HFS)
using the analysis of variance with post-hoc multiple comparison
procedures (Bonferroni test). For behavioral tests (open field,
beam test), we applied the Kruskal-Wallis one way analysis of
variance on ranks followed by a pairwise multiple comparison
procedures (Tukey-Kramer test).
Results
GAD65Ab Epitope Specificities in Autoimmune
Movement Disorders
Our analysis of GAD65Ab epitope specificities and titers in
patients with different neurological syndromes, revealed no
significant differences in GAD65Ab titers (Figure 1A) or
in recognition of the b96.11-defined epitope (Figure 1C).
However patients with SPS recognized the b78-defined epitope
significantly better than patients with ataxia (P = 0.03) or LE
(P = 0.01) (Figure 1B). Patients with ataxia showed higher
recognition of the b78-defined epitope than patients with LE,
however this difference was not significant (P = 0.07). Notably,
one LE patient was diagnosed with stiff-leg syndrome. This
patient showed the strongest recognition of the b78-defined
epitope in the LE group. Ten patients with T1D were included
in our analysis to confirm our previous finding that GAD65Ab
in T1D patients show preferred binding to the b96.11-defined
epitope, while lacking binding to the b78-defined epitope (Padoa
et al., 2003).
Co-localization of GAD65 with GABAergic
Vesicles is Interrupted by b78
To establish whether GAD65Ab interfere with the association
of GAD65 and GABAergic vesicles, we immunoprecipitated
GABAergic vesicles in the presence of GAD65Ab. Synaptic
vesicles were isolated from rat brain and incubated with
or without b78, b96.11, or HAA1. GABAergic vesicles were
precipitated with monoclonal antibody N-GAD65mAb. Immune
complexes were analyzed by Western blot for the presence of
synaptophysin (Figure 2). Precipitation of GABAergic vesicles
by N-GAD65mAb-PAS was abolished through competition
with uncoupled N-GAD65mAb, showing specificity of the
immune precipitation. We found a significant reduction of
the synaptophysin signal in the presence of b78, while b96.11
and HAA1 showed no effect. These results suggest that b78
interferes with the association of GAD65 to GABAergic vesicles.
Previously we established that binding of monoclonal antibody
N-GAD65mAb did not interfere with binding of b96.11 or b78
to GAD65 (Fenalti et al., 2008), ensuring that the observed
results were not caused by displacement of N-GAD65mAb from
GAD65.
In Vitro Analysis of the Effects of b78 and b96.11
on Cerebellar GABAergic Inhibition
Focal stimulation within the molecular layer in the cerebellar
cortex produces inhibitory postsynaptic currents (IPSCs) in
Purkinje cells, which are mediated by GABA released from
basket cells. Responder cells were defined as showing Ab-induced
inhibition 3 min after the bath application, which lasted for more
than 20 min and an inhibition rate >20% (percent changes in
the IPSC before and after was below 80%). While application of
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FIGURE 1 | GAD65Ab titers and epitope specificities in patients with
neurological disorders. GAD65Ab titers (A) and epitope specificities (B,C)
in patients with SPS, cerebellar ataxia, SPS, LE, and type 1 diabetes patients
without neurological symptoms were evaluated. Results for the LE patient that
presents also stiff-leg syndrome are indicated as an open circle. GAD65Ab
titers are presented as U/ml. Binding to GAD65 in the presence of rFab is
presented as percent related to non-competed binding (set as 100%). Median
binding is indicated. Significant differences are shown. Cut-off value for
significant competition of GAD65Ab binding by recombinant Fab is indicated
as the dotted line in panels (B,C). * = P < 0.05, ** = P < 0.01.
either b78 or b96.11 suppressed the amplitude of IPSCs in 12/24,
and 9/26 tested cells, respectively (Figure 3), the time-course of
the synaptic depression in responder cells differed considerably
between the antibodies (Figure 3A). Administration of b78
resulted in a gradual decrease of the IPSC amplitude, beginning
5–6 min after the application (mean: 67.2± 4.2% of the control),
and reaching a final decrease of 49.6 ± 5.7% compared to the
control, which lasted for more than 30 min. Reduction of the
IPSC amplitude following administration of b96.11 occurred
relatively faster, reaching 65.7 ± 5.8% of the control already
5–6 min after the application, however, the inhibitory effects
tended to attenuate and the amplitude recovered to 78.0 ± 6.1%
of the control after 25–30 min. Therefore no significant
FIGURE 2 | Effect of GAD65Ab on association of GAD65 with
GABAergic vesicles. Synaptic vesicles were incubated with monoclonal
antibodies b78, HAA1, b96.11, or N-GAD65mAb for 1 h on ice. No antibody
was added for the control sample. GABAergic vesicles were isolated as
outlined in the inset sketch and the immunoprecipitated proteins were
analyzed for the presence of synaptophysin by Western blot. (A)
Representative Western blot analysis. (B) Densiometric analysis from three
independent experiments. Results are presented as percentage of the
corresponding control sample. Error bars represent the standard deviation of
the mean. Inset: schematic representation of the experimental set-up.
differences were observed in the short-term reduction of IPSC
amplitude (5–6 min after antibody administration) between in
slices perfused with b78 and in slices perfused with b96.11 (67.2%
and 65.7% and 67.2%, respectively, P = 0.95), whereas the long-
term effect (25–30 min after antibody administration) of b78
resulted in a significantly stronger reduction in IPSC amplitude,
as compared to b96.11 (49.6% and 78.0%, respectively, P = 0.003;
Figure 3B).
The ratio of the magnitude of the second IPSC to that
of the first IPSC to paired-pulse stimuli was defined as
the paired-pulse ratio (PPR). During the inhibitory period
caused by both antibodies, PPR was increased, suggesting
a presynaptic mechanism. Miniature IPSCs (mIPSCs) were
analyzed to elucidate changes underlying presynaptic depression.
Application of b78 decreased the amplitude of mIPSCs and
reduced frequency in most of the tested cells (n = 12)
(Figures 4A,B). Thus, the statistical analysis was calculated from
all tested cells. The cumulative curve of the amplitudes was
significantly higher after b78 application (Kolmogorov-Smirnov
test; P = 0.01). Correspondingly, the cumulative curve of the
inter-event intervals was significantly lower after b78 application
(Kolmogorov-Smirnov test; P = 0.007). After the perfusion of
b78, the amplitude decreased to 87.0 ± 3.5% of the control
(n = 12) and the frequency was reduced to 84.7 ± 4.4% of the
control (n = 12) (Figure 4C). Control monoclonal Ab HAA1
produced no effect on miniature IPSCs (n = 12) in amplitude or
frequency (99.1 ± 3.4% and 103.2 ± 2.3% of the controls, the
mean and SEM 15–17 min after the application, respectively).
Amplitude and frequencies observed after application of b78
were significantly lower when compared to those recorded
after application of HAA1 (Amplitude: t22 = 2.39, P = 0.03;
Frequency: t22 = 3.68, P = 0.001, Figure 4D). These results
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FIGURE 3 | Inhibition of GABAergic synaptic transmission by
monoclonal GAD65Ab. (A) Time-course of changes in evoked IPSC
amplitude by b78 (blue circles, n = 12) and b96.11 (red circles, n = 9) in
cerebellar Purkinje cells. Each point represents the mean (±SEM). Inset:
Responses are shown as averages of ten consecutive sweeps recorded
before (a, black lines) and after (b, blue line for b78 and red line for b96.11)
application of diluted-antibodies, respectively. Traces in a and b were obtained
at the time points indicated in the left panel. (B) Summary of the
antibody-induced suppressive effects on the inhibitory synaptic transmissions.
To compare the effects of monoclonal antibodies on the inhibitory
transmission, we set two time windows that covered early onset of inhibition
(5–6 min, open bars) and sustained-inhibition after wash-out of antibodies
(25–30 min, closed bars). Asterisks indicate the significance level compared
with each groups by Tukey-Kramer multiple comparison test. Each point
represents mean ± SEM.
supported our hypothesis that monoclonal GAD65Ab reduce
GABAergic inhibition via reduced concentrations of presynaptic
released GABA.
GAD65 Knockout Mice
The above evaluations were also performed in wild-type C57BL/6
mice (WT) and GAD65-knockout mice (GAD65-KO). Using the
same criteria as in the rat experiments we defined responder
and non-responder cells in the WT mice. Numbers of responder
and non-responder cells in WT and GAD65-KO are shown
in Table 2. Six out of 14 tested cells met the criteria of
responder cells. Importantly, none of the nine cells studied from
GAD65-KO met the criteria of responder cell (Table 2).
FIGURE 4 | Effect of b78 on miniature IPSCs. (A) An example of changes
in miniature IPSCs (mIPSCs). mIPSCs were recorded from a PC before (left)
and 15 min after the application of b78. (B) Cumulative curves for the
amplitude (left) and the inter-event intervals (right) distributions of mIPSCs
were compiled from 2 min records before (black lines) and after (red lines) the
b78 application, respectively. (C) Summary data for the effects of b78 on the
mIPSC amplitude (left; Baseline, 52.6 ± 3.8 pA; 15–17 min; 44.6 ± 2.9 pA;
t11 = 2.67, P = 0.02, n = 12) and frequency (right; Baseline, 5.1 ± 0.5 Hz;
15–17 min; 4.3 ± 0.5 Hz; t11 = 3.65, P = 0.004, n = 12) in PCs. Each column
represents mean ± SEM that is calculated from individual mIPSC events for
2 min before (baseline) and 15 min after the b78 application in 12 tested cells.
(D) The extent of change of the amplitude (left) and the frequency (right) of
mIPSCs by b78 (n = 12) was compared with that observed after
administration of control HAA1 (n = 12). The percent of change was calculated
by the proportion of the value after 15–17 min to that before the application of
each monoclonal Ab.
Compared to cells from GAD65-KO, the six WT responder
cells showed significantly lower IPSC amplitude changes during
the 15–30 min period following b78 application (t13 = −5.68,
p = 1 × 10−4) (Figure 5). These results indicate that while
b78 suppressed IPSCs in WT, similar to our results in rats,
GAD65-KO cells show no response to b78 injection.
TABLE 2 | Actions of monoclonal Ab b78 on stimuli-evoked IPSCs.
Responder Non-responder Total cells
cells cells analyzed
Wild-type 6 8 14
GAD65 knockout 0 9 9
Sprague-Dawley rats 12 12 24
Numbers of responder and non-responder cells are reported in studies of
cerebellar slices obtained from WT and GAD65-KO mice, and rats, respectively.
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FIGURE 5 | Response of GAD65-KO mice to b78 injection. Left panel:
Mean IPSC amplitude changes of the six responder cells in WT (open circles)
and all tested cells in GAD65-KO (gray circles). Significant differences were
observed between the two groups during the 15–30 min after b78 applications,
(p = 1 × 10−4). Right panel: Responses are shown as averages of eight
consecutive sweeps recorded before (a, thin lines) and after (b, thick lines)
application of diluted-antibody, respectively. Traces in a and b were obtained at
the time points indicated in the left panel.
Classical Conditioning in Mice
Classical eyeblink conditioning using both trace and delay
paradigms was performed in non-injected mice and in animals
injected with b78. During the trace paradigm, all animals showed
evidence of learning, as CR percentages increased progressively
over time. Control animals showed 33.6 ± 6.6% (mean ± SEM,
n = 10) CRs on the 1st conditioning day, and reached peak values
by the 4th conditioning session (43.7± 5.1%). Mice injected with
b78 showed 29.2 ± 5.9% during the 1st conditioning session
and 44.5 ± 4.8% during the 3rd. No significant differences
in CR percentages or relative amplitude of the evoked CR for
the two groups were detected (data not shown). Moreover,
no significant differences were detected when comparing the
conditioned responses in animals receiving b78 and control
animals (data not shown).
However, significant differences were observed for the area
of rectified EMGs collected at the CS-US interval during delay
conditioning (Figure 6). Here conditioned eyelid responses
evoked in controls were significantly larger as compared to those
in mice administered with b78 (F(1,14) = 4.6; P < 0.05).
Modulation of Corticomotor Responses in Rats
Next we determined whether the interference of monoclonal
GAD65Ab on GABA neurotransmission had an effect on
the electrophysiology. We infused rats in their cerebellum
with Ringer (Group 1), b96.11 (Group 2) or b78 (Group 3).
Corticomotor responses evoked in interosseus muscles following
stimulation of the contralateral motor cortex were recorded. In
Groups 1–3, latencies of corticomotor responses in interosseus
muscles were between 5.1 ms and 6.7 ms in forelimbs and
between 8.3 and 9.4 ms in hindlimbs. The range of peak-
to-peak intensities of M responses was between 3.6 and
6.5 mV (Figure 7A). At baseline, amplitudes of MEPs were
similar in all groups for forelimbs (range of intensities:
659–884 µV) and hindlimbs (range of intensities: 673–872
µV) (Figure 7A, Baseline). Similarly, no differences were
observed after injection (Figure 7A, Post-injection). However,
after application of trains of stimuli (HFS) over the premotor
cortex, rats injected with Ringer or b96.11 showed marked
facilitation of the pairing effect following HFS (Figure 7A,
Post-HFS). By contrast, injection of b78 induced a striking
block of this facilitation. A similar observation was made
for hindlimbs (data not shown). In addition, using ISIs
of 10 and 14 ms between the medialis nerve and the
contralateral motor cortex led to similar findings (data not
shown).
For MEPs in forelimbs, the effect of the paired-pulse
procedure (ratios CMR/UMR = ratios paired corticomotor
responses/unpaired corticomotor responses) was assessed in the
three treatment groups and in the three states (basal state, post-
injection and post-HFS) (Figure 7B). A conditioning effect was
found for all three groups of rats in all states (P < 0.001;
Bonferroni test: P < 0.05). However, the enhancement of the
pairing effect associated with HFS of the premotor cortex was
significantly higher in animals injected with Ringer solution or
b96.11 as compared to animals injected with b78 (P < 0.001).
In the basal condition, the mean ratios CMR/UMR were
similar for animals injected with Ringer solution, b96.11, or
b78 (1.28 ± 0.06, 1.24 ± 0.06 and 1.26 ± 0.05, respectively).
After injection, no significant differences in the mean ratios
CMR/UMR were observed between the groups (1.27 ± 0.05,
1.30 ± 0.04 and 1.25 ± 0.04, respectively). However, after HFS,
the mean ratios CMR/UMR for animals injected with Ringer
solution or b96.11 were significantly higher (1.50 ± 0.07, 1.52
± 0.05, respectively), as compared to animals administered
with b78 (1.15 ± 0.04) (inter-group difference: P < 0.001).
Similar observations were made for the hindlimbs (data not
shown).
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FIGURE 6 | Learning curves and eyelid performance collected from
controls (saline) and experimental (b78) mice during a delay
conditioning paradigms. Spreading of b78 in the deep cerebellar nuclei was
confirmed by immunohistochemistry. (A) Presence of b78 in deep nuclei areas
of the right cerebellar hemisphere. The injection site in the contralateral area is
indicated by the asterisk. (B) Enlargement of the marked area in panel (A).
(C) Purkinje cells of a lobule area proximal to the injection site. Abbreviations:
IntA, anterior part, La, lateral part. Calibration bars: (A): 200 µm, (B,C) 50 µm.
(D) Conditioned eyelid responses evoked in controls were significantly larger
(F(1,14) = 4.6; P = 0.05; see asterisks) than those evoked in b78 animals.
In rats administered with b78 in the fastigial nucleus, the
facilitation of the pairing effect following HFS was very similar to
the values observed in animals injected with Ringer solution or
b96.11. For forelimbs, the mean ratios CMR/UMR (± SD) were
1.30 ± 0.06 in the basal condition, 1.33 ± 0.07 post-injection
and 1.59 ± 0.08 post-HFS. For hindlimbs, the mean ratios
CMR/UMR (± SD) were 1.28 ± 0.07 in the basal condition,
1.29± 0.05 post-injection and 1.55± 0.07 post-HFS.
Behavioral Data
Effects of GAD65Ab on exploration behavior (open field) and
locomotor activity (beam test) were assessed. For exploration
behavior the number of squares crossed in an open field by
rats infused with b78, b96.11, Ringer solution, or non-injected
animals was analyzed (Figure 8). The administration of b78
decreased the exploration behavior of rats in the open field
significantly as seen in the number of squares crossed compared
to the other groups (P < 0.001). Gait was moderately irregular.
Both groups injected with b96.11 and Ringer solution showed
a slight but significant decrease in exploration behavior as
compared to the group without injection (P < 0.05), however
the animals’ gait was regular.
For assessment of locomotor activity the animals had to
traverse an elevated horizontal beam (beam test). Displacement
times were counted. Rats administrated with b78 showed
significantly greater displacement times compared to the other
groups (P< 0.001). Moreover, their locomotion was slower, with
foot slips but without falling. In addition, we also found that
b96.11 slightly increased the displacement times as compared to
the sham group (no infusion) and the group infused with Ringer
solution (P < 0.05).
Discussion
We now provide critical findings for the understanding of the
pathogenesis of GAD65Ab. The observation of disease-specific
GAD65Ab in neurological disorders led to the hypothesis that
GAD65Ab target and inhibit GAD65 in these diseases. Passive
transfer experiments supported this hypothesis (Geis et al.,
2011; Manto et al., 2011; Hampe et al., 2013; Hansen et al.,
2013; Vega-Flores et al., 2014). Importantly, IgG from patients’
CSF suggested that GAD65Ab acted on synaptic transmissions
in an epitope-dependent manner, which may result in the
development of neurological symptoms. IgG from ataxia patients
depressed the cerebellar inhibitory synaptic transmissions in
slices (Ishida et al., 1999; Mitoma et al., 2003) and impaired
the cerebellar modulation on the motor cortex (Manto et al.,
2011). In contrast, IgG from patients with T1D had no effect
on synaptic transmissions or modulation on the motor cortex
(Ishida et al., 1999; Mitoma et al., 2003; Manto et al., 2011).
These effects were confirmed in vivo (Geis et al., 2011; Manto
et al., 2011; Hampe et al., 2013; Hansen et al., 2013; Vega-
Flores et al., 2014). However, to establish a pathogenic role for
GAD65Ab, we need to address (a) The mechanism by which
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FIGURE 7 | Effect of GAD65Ab on conditioned corticomotor responses
and on motor evoked potentials illustrated by ratio of paired/unpaired
corticomotor responses. (A) Superimposition of averaged motor evoked
potentials (MEPs) obtained without preceding peripheral stimulation (unpaired
responses, thin traces) and with a pairing stimulus (thick trace). Pairs of
corticomotor responses are shown at baseline (before injection; traces on the
left), after injection (middle traces), and after high-frequency stimulation
(post-HFS; traces on the right). From top to bottom: infusion of Ringer
solution, infusion of b96.11, and infusion of b78. Averaged MEPs in left
interosseus muscles (forelimbs) are illustrated (stimulation of right motor
cortex). Note the marked increase in the intensity of paired responses in
forelimb after HFS for the rat injected with Ringer solution and the rat
injected with b96.11. By contrast, b78 induces a striking block of the
facilitatory effect normally exerted by HFS of the premotor cortex upon
conditioned corticomotor responses. (B) Effects of GAD65Ab injection in left
interpositus nucleus on the ratios of paired corticomotor responses (CMR)
divided by unpaired responses (UMR) in Groups 1–3. Data related to MEPs
in left interosseus muscles (forelimbs) are illustrated. Black columns: infusion
of Ringer solution (n = 9); gray columns: infusion of b96.11 (n = 10); white
columns: infusion of b78 (n = 7). Paired responses are investigated at
baseline, post-injection and after high-frequency stimulation (post-HFS).
Values are mean ± SD. **P < 0.01.
GAD65Ab inhibit GABAergic neurotransmission, e.g whether
the depression occurs presynaptic or postsynaptic; and (b) The
ability of GAD65Ab to elicit deficits in cerebellar coodination
on reflexes, gait, and limb movements in vivo. To address
these critical problems, we conducted the further advanced
analysis using monoclonal GAD65Abs in the present study.
Moreover, we addressed the possibility that the observed effects
are caused by the binding of GAD65Ab to proteins other than
GAD65.
Our study utilized two well-defined monoclonal GAD65Ab
to focus on epitope-specific effects of GAD65Ab and to eliminate
the impact of other factors present in patients’ sera. The
specificity of GAD65Ab b78 is associated with SPS, while that of
GAD65Ab b96.11 is associated with T1D and only rarely found
in patients with SPS (Raju et al., 2005; Manto et al., 2007). These
previous findings were now confirmed and extended in our
analysis of GAD65Ab epitope patterns in GAD65Ab-positive
neurological disorders. SPS and ataxia patients showed strong
recognition of the b78-defined epitope, while LE patients showed
no significant recognition of this epitope. The presence of
b96.11-like GAD65Ab in sera of SPS and CA patients is likely
due to the co-diagnosis of T1D in many of these patients.
Overall, the GAD65Ab response in SPS and CA patients is
skewed towards a b78-like epitope specificity, while that in T1D
patients is skewed towards a b96.11-like epitope specificity. A
more specific identification of the GAD65Ab epitope is hindered
by the conformational characteristic for autoepitopes (Mackay
and Rowley, 2004).
Our investigation of the mechanisms involved in the
GAD65Ab-mediated pathogenesis suggests a b78-specific
interference with GABAergic synaptic transmission. Cerebellar
slice experiments suggested an inhibitory effect of GAD65Ab on
the GABAergic synaptic transmission between basket cells and
Purkinje cells, with distinct effects of b78 and b96.11. GAD65Ab
b78 depressed the inhibitory synaptic transmission with a
gradual time course and lasting suppressive effect, while b96.11
caused only a transient depression of transmission. Previous
studies using slice-patch recordings have shown that GAD65Ab
in ataxia patients act on the terminals of GABAergic neurons to
suppress the release of GABA, thereby depressing the inhibitory
transmission with a gradual and long-lasting time course (Ishida
et al., 1999; Mitoma et al., 2003). The synaptic impairment by
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FIGURE 8 | Effect of GAD65Ab on behavior of rats as assessed in
open field test and elevated beam test. (A) Effects of bilateral
administration of GAD65Ab in the interpositus nucleus on exploration
behavior in rats (open field test). Four groups of five rats were assessed.
The number of squares crossed was measured over a period of 3 min
(five trials per rat). Box plots showing median values, p25 and p75 with
outliers. **P < 0.001, *P < 0.05. (B) Displacement times (expressed in
seconds) during the horizontal beam test. Four groups of three rats were
assessed. Median with mean values (dotted lines) are shown, as well as
p25/p75 and outliers. **P < 0.001, *P < 0.05.
GAD65Ab in patients’ CSF was mimicked by b78 and not b96.11.
Our observation of the decrease in GABA release by the PPR
analysis indicates that b78 may affect a presynaptic mechanism
that induces this synaptic impairment.
In contrast to b78, b96.11 affected neither GAD65 enzyme
activity nor the exocytosis of vesicle (Padoa et al., 2003; Manto
et al., 2007). Although b96.11 elicited a temporal inhibition in
our transmission experiment, the intra-cerebellar administration
of b96.11 had no effect on the activity in the cerebello-cerebral
circuits (Manto et al., 2011). Thus, the inhibition by b96.11
in slices appears to have no significant physiological effects
due to its temporal nature. On the other hand, both b78
and b96.11 produced the same early inhibition in the time-
course of percentage changes in IPSCs (see Figure 3). Thus, the
early component induced by both Abs in slices might have no
physiological significance in vivo, whereas the late component
specific to b78 might be associated with changes in cerebello-
cerebral circuits in vivo.
Our experiments in GAD65-KO mice confirmed that the
observed effect evoked by b78 administration is GAD65-specific.
B78 induced a gradual and long-lasting depression in roughly
50% of the tested cells in rats and WT mice. By contrast, no
depression was observed in any of the tested cells obtained from
GAD65-KO mice. It is unclear why only 50% of Purkinje cells
in cerebellar slices responded to treatment with b78 or b96.11.
One possible explanation may be an unstable accessibility of
GAD65Ab to intracellular GAD65. Internalization of antibodies
by neurons, which enables the antibody to bind intracellular
antigens, has been suggested (Geis et al., 2010; Manto et al.,
2011), and was confirmed by us (Vega-Flores et al., 2014),
but this process may depend on neuronal activities, or the
internalized Ab concentration may be suboptimal. Alternatively,
the residual presence of GABAergic vesicles in the nerve
terminals may mask the effect of b78.
We investigated the mechanism by which blockade of
GAD65 in the presynaptic terminals impaired GABA release.
Besides generating GABA necessary for fine-tuning of GABA
concentrations at the synapse, GAD65 is associated with the
cytosolic face of GABAergic vesicles (Jin et al., 2003). Previous
studies demonstrated that GAD65 mediates the shuttling of
GABAergic vesicles to the synaptic cleft and that cleavage of
GAD65 from the vesicles results in reduced GABA transport
(Buddhala et al., 2012). Our co-immunoprecipitation results
indicate that b78 and not b96.11 interferes with the binding of
GAD65 to GABAergic synaptic vesicles. Our results however do
not rule out that b78 acts also through its inhibition of GAD65
enzyme activity.
Based on our results, two independent events in the
presynaptic mechanisms may cause the decrease in GABA
release. First, b78 may reduce the release probability of
GABAergic vesicles, as indicated by the decrease in the frequency
of mIPSCs (Saitow et al., 2009). Second, b78 may inhibit GAD65
enzyme activity or block GAD65-mediated vesicular transport, as
indicated by a tendency to smaller amplitudes of mIPSCS. These
duplicated actions are in good agreement with previous reports
that b78 inhibited the enzyme activity of GAD65 and interfered
with the exocytosis of GABA-containing vesicle (Raju et al., 2005;
Manto et al., 2007).
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FIGURE 9 | Schematic diagram of pathogenic Abs in cerebellar
circuits. Pathogenic b78 acts on the terminals of GABAergic neurons to
reduce GABA release. The decrease of GABA release alters the activities of
PCs and cerebellar nuclei neurons, resulting in disorganized outputs to motor
control centers. PC: Purkinje cells, GABAergic In: GABAergic interneurons,
PF; parallel fibers, MF; mossy fibers. Arrows indicate flow of signals through
the cerebellum. Excitatory neurons are indicated by white circles, while
inhibitory neurons by black circles.
After having established that the in vitro application of b78
impaired the release of GABA, we addressed the b78-induced
loss of cerebellar coordination in vivo. Therefore we conducted a
series of experiments including classical eyeblink reflex, cerebro-
cerebellar linkage, gait, and exploratory behavior.
The classical eyeblink conditioning test demonstrated
that while blockage of GABAergic activity on cerebellar
interpositus neurons by b78 did not modify learning curves, it
resulted in significantly smaller conditioned responses during
delay conditioning. These results suggest that b78 inhibits
cerebellar circuits affecting the performance of conditioned
eyelid responses, but not the acquisition process. Similar
findings were reported in Lurcher mice (devoid of Purkinje
cells; Porras-García et al., 2010), and reports in rabbits and
cats indicate that alterations in the functional capabilities
of cerebellar circuits produce significant changes in the
performance of conditioned eyelid responses, but not in the
learning curves (Welsh and Harvey, 1989; Jiménez-Díaz et al.,
2004).
Our study of the effects of trains of HFS on the premotor
area on corticomotor responses shows that infusion of b78 in
the cerebellar interpositus nucleus of the rat markedly impairs
the facilitatory effect exerted by the premotor cortex in a paired
stimulation paradigm. This impairment was only observed for
b78, suggesting that this effect is epitope-specific. Our results
cannot be explained by a depressive effect of monoclonal
GAD65Ab on spinal facilitation. Indeed, as we have shown
previously, infusion of GAD65Ab in the interpositus nucleus
enhanced the excitability of the spinal cord (Manto et al., 2007).
In addition, we observed similar deficits using ISIs (between
the medialis nerve and the contralateral M1) of up to 14 ms,
excluding an impairment of spinal facilitation.
Finally, our behavioral findings show that administration of
GAD65Ab to the cerebellum induced a significant decrease in
exploratory behavior. Previously GAD65-KO mice were shown
to exhibit increased anxiety-like responses (Kash et al., 1999).
Abnormal GABAergic synaptic transmission is likely to result in
gait and movement abnormalities, as suggested by the increased
displacement times of b78-injected rats on the elevated beam.
A recent study showed that the intrathecal passive transfer of
IgG isolated from a SPS patient to rats induced anxiety-like
behavior, with no obvious changes in activity levels in the open
field (Hansen et al., 2013). The effect of the purified IgG on
GAD65 enzyme activity was not investigated in this earlier study,
therefore it is possible that differences in epitope specificities may
result in these distinct behaviors.
To our knowledge this is the first study that presents
mechanistic detail on the pathogenic mechanism of monoclonal
GAD65Ab on the cerebellum. The effects of monoclonal
GAD65Ab mimicked those of patient’s IgGs in slices and in
modulation on motor cortex in vivo (Ishida et al., 1999; Mitoma
et al., 2003). Thus, our results support the idea that epitope
specific GAD65Ab cause a disease-specific level of impairment
in cerebellar circuits, leading to different neurological symptoms
(Manto et al., 2011). We propose, that b78-mediated inhibition
of GABA-release from GABAergic interneurons on cerebellar
Purkinje cells elicits a dual impairment on synaptic transmissions
on Purkinje cells; depression of inhibitory synapses and
enhancement of excitatory synapses (Ishida et al., 1999; Mitoma
et al., 2003; Figure 9). Furthermore, the dual impairment should
occur similarly in cerebellar nuclei neurons. Consequently, the
b78-induced deficits in GABA-release would elicit disorganized
cerebellar outputs on various motor control centers. Unlike
cerebral cortex pyramidal cells, Purkinje cells have no local
inhibitory feed-back circuit that prevent burst activation and are
thusmaladapted to prevent hyperexcitability (De Schutter, 1995).
Thus, the dual impairment, consisting of a decrease in GABA
and an increase in glutamate, could cause the degeneration of
Purkinje cells observed in ataxia.
Our results do not rule out a possible pathogenic role
of other autoantibodies in ataxia and SPS. However the use
of purified monoclonal GAD65-specific antibodies eliminates
these factors from our analysis. Together with previous findings
that the absorption of GAD65Ab completely diminished the
CSF-induced depressive effect in rat cerebellar slices (Ishida
et al., 2008), the present results support a pathogenic role of
GAD65Ab. Our data suggest a possible therapeutic approach for
the treatment of neurological patients with high GAD65Ab titers,
via removal or selective blockage of b78-like GAD65Ab.
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